Table 1.

Patient characteristics

Patient #	Gender	Age	Disease duration (years)	Diagnosis	MBP-induced CD4+ T-cell proliferation1	HLA-DR2	HLA-DQ2	MRI3	EDSS4
1	F	38	New	RRMS	+	4, 13	3, 6	6	0
2	F	40	New	CIS	−	14, 15	5, 6	2	1
3	F	39	New	RRMS	−	4, 15	3, 6	3	1
4	M	30	1	RRMS	−	3, 7	2	0	1
5	F	25	1	RRMS	+	15, 16	5, 6	12	0
6	F	28	1	RRMS	+	14, 15	5, 6	n.d.	2·5
7	M	40	2	RRMS	−	1, 15	5, 6	1	2
8	F	46	2	RRMS	−	3, 13	2, 6	0	2
9	F	29	2	RRMS	−	15	6	0	5
10	F	36	12	RRMS	−	3, 13	2, 3	n.d.	2
11	M	25	3	RRMS	−	4, 13	3, 6	0	0
12	F	35	3	RRMS	−	8, 15	4, 6	2	0
13	F	27	3	CIS	−	8, 15	4, 6	2	0
14	F	37	3	RRMS	−	13, 15	6	0	6
15	M	25	2	RRMS	−	4, 15	3, 6	n.d.	1·5
16	M	35	4	RRMS	−	3, 15	2, 6	0	1
17	M	41	7	RRMS	−	4, 7	2, 3	0	0
18	M	29	9	RRMS	+	1, 15	5, 6	2	2
19	F	44	9	RRMS	−	3, 15	2, 6	0	3
20	F	29	12	RRMS	+	3, 15	2, 6	0	1
21	F	35	2	RRMS	−	7, 15	2, 6	n.d.	0
22	M	39	18	RRMS	−	1, 3	2, 5	0	1

RRMS, relapsing–remitting multiple sclerosis; CIS, clinically isolated syndrome; EDSS, Expanded Disability Status Scale; n.d, not determined.

¹Positive CD4⁺ T-cell proliferation (net proliferation > 1%).

²Human leucocyte antigen (HLA) typing was carried out in-house using low-resolution technology.

³Number of active lesions as determined by magnetic resonance imaging.

⁴EDSS⁴⁴ was measured at the time of blood sampling.